Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

2 articles from the last 90 days matching "immunotherapy"

Clinical trialCLINICALTRIALSApr 3

Trial Now Recruiting: Understanding of Rare Inflammatory Arthritis in Comparison to Classical Inflammatory Arthritis : Tissular Observations and Immune Infiltrate Characterization : the UTOPIC Project (NCT07302074)

Researchers are looking for 100 people with rare types of joint inflammation to better understand how these conditions develop and damage joints. Some of these inflammatory arthritides occur alongside rare autoimmune diseases like systemic sclerosis, while others develop as side effects from cancer immunotherapy drugs. By studying tissue samples and immune cells from patients, scientists hope to discover why these conditions happen and potentially develop better treatments.

WHY IT MATTERSIf you have rare inflammatory arthritis, systemic sclerosis with joint involvement, or developed joint inflammation after cancer immunotherapy, this trial could help researchers understand your condition better and may lead to more targeted treatments in the future.
→ You can act on thisSystemic SclerosisInflammatory ArthritisImmune Checkpoint Inhibitor-Related Inflammatory ArthritisRead →
Clinical trialCLINICALTRIALSMar 26

Trial Now Recruiting: Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors (NCT03866382)

Researchers are testing whether combining three cancer drugs—nivolumab, ipilimumab, and cabozantinib—can help treat rare cancers of the bladder, kidney, prostate, and other urinary system organs. This phase 2 trial is actively recruiting 314 patients to see if this drug combination works better than current treatments. The study is being run by the National Cancer Institute.

WHY IT MATTERSThis trial offers patients with rare genitourinary cancers (like collecting duct carcinoma, kidney medullary carcinoma, and rare bladder variants) access to a novel three-drug combination that may be more effective than standard treatments currently available.
→ You can act on thisBladder AdenocarcinomaBladder Neuroendocrine CarcinomaChromophobe Renal Cell CarcinomaRead →

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases